CoChat

Long-Term Stimulant Treatment Affects Brain Dopamine Transporter Level in Patients with Attention Deficit Hyperactive Disorder

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Brain dopamine dysfunction in attention deficit/hyperactivity disorder (ADHD) could explain why stimulant medications, which increase dopamine signaling, are therapeutically beneficial. However while the acute increases in dopamine induced by stimulant medications have been associated with symptom improvement in ADHD the chronic effects have not been investigated. METHOD: We used positron emission tomography and [(11)C]cocaine (dopamine transporter radioligand) to measure dopamine transporter availability in the brains of 18 never-medicated adult ADHD subjects prior to and after 12 months of treatment with methylphenidate and in 11 controls who were also scanned twice at 12 months interval but without stimulant medication. Dopamine transporter availability was quantified as non-displaceable binding potential using a kinetic model for reversible ligands. RESULTS: Twelve months of methylphenidate treatment increased striatal dopamine transporter availability in ADHD (caudate, putamen and ventral striatum: +24%, p<0.01); whereas there were no changes in control subjects retested at 12-month interval. Comparisons between controls and ADHD participants revealed no significant difference in dopamine transporter availability prior to treatment but showed higher dopamine transporter availability in ADHD participants than control after long-term treatment (caudate: p<0.007; putamen: p<0.005). CONCLUSION: Upregulation of dopamine transporter availability during long-term treatment with methylphenidate may decrease treatment efficacy and exacerbate symptoms while not under the effects of the medication. Our findings also suggest that the discrepancies in the literature regarding dopamine transporter availability in ADHD participants (some studies reporting increases, other no changes and other decreases) may reflect, in part, differences in treatment histories.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0063023

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Averaged dopamine transporter availability images. Averaged dopamine transporter availability images of ADHD (n = 18) and control (n = 11) subjects prior to and after 12 months oral MP treatment as well as baseline and 12 follow up scans of control subjects. The images are scaled with respect to the maximum value (distribution volume ratio) obtained on the ADHD subjects at follow up visit and presented using the rainbow scale. Red represents the highest value and dark violet represents the lowest value.
Figure 1 Averaged dopamine transporter availability images. Averaged dopamine transporter availability images of ADHD (n = 18) and control (n = 11) subjects prior to and after 12 months oral MP treatment as well as baseline and 12 follow up scans of control subjects. The images are scaled with respect to the maximum value (distribution volume ratio) obtained on the ADHD subjects at follow up visit and presented using the rainbow scale. Red represents the highest value and dark violet represents the lowest value.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. CK Conners, 1998, Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring, J Clin Psychiatry, 59 Suppl 7, 24
  2. ND Volkow, 2013, Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with ADHD, Journal of neuroscience

Cited by

See all 175

Metadata

Authors
Wang, G.-J., Volkow, N. D., Wigal, T., Kollins, S. H., Newcorn, J. H., Telang, F., Logan, J., Jayne, M., Wong, C. T., Han, H., Fowler, J. S., Zhu, W., & Swanson, J. M.
Affiliations
  • Brookhaven National Laboratory (US)
  • National Institutes of Health (US)
  • University of California, Irvine (US)
  • Duke University (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Stony Brook University (US)
Corresponding author
Wang, Gene-Jack
Venue
PLoS ONE
Published
2013-05-15
Volume
8
Issue
5
Pages
e63023
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2059137431
Cited by
144
References
29
Citations by year
2026: 6 · 2025: 7 · 2024: 9 · 2023: 11 · 2022: 13 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 15 · 2016: 10 · 2015: 8 · 2014: 15 · 2013: 5
FWCI
8.81
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • U.S. Department of Energy (DE‐ACO2‐76CH00016, 76CH00016)
  • Orexigen Therapeutics
  • Stony Brook University
  • National Institutes of Health
  • National Institute on Alcohol Abuse and Alcoholism (Z01AA000550)
  • National Institute of Mental Health (R01MH066961)
  • National Center for Research Resources (M01RR010710)
  • Biological and Environmental Research
  • Brookhaven National Laboratory (DE-ACO2-76CH00016)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
attention deficit hyperactivity disorder, dopamine transporter, methylphenidate, striatum, caudate nucleus, putamen, ventral striatum, treatment efficacy, adult ADHD
MeSH terms
Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Caudate Nucleus, Cocaine, Female, Humans, Male, Methylphenidate, Putamen, Case-Control Studies, Radiopharmaceuticals, Positron-Emission Tomography, Dopamine Plasma Membrane Transport Proteins, Young Adult, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.